1. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress Author(s): Booz George W. Source: FREE RADICAL BIOLOGY AND MEDICINE Volume: 51 Issue: 5 Special Issue: SI Pages: 1054-1061 DOI: 10.1016/j.freeradbiomed.2011.01.007 Published: SEP 1 2011 Times Cited: 1 (from All Databases)
  2. Cannabis in Palliative Medicine: Improving Care and Reducing Opioid-Related Morbidity Author(s): Carter Gregory T.; Flanagan Aaron M.; Earleywine Mitchell; et al. Source: AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE Volume: 28 Issue: 5 Pages: 297-303 DOI: 10.1177/1049909111402318 Published: AUG 2011 Times Cited: 0 (from All Databases) 
  3. Neuroprotective Effects of Phytocannabinoid-Based Medicines in Experimental Models of Huntington's Disease Author(s): Sagredo Onintza; Pazos M. Ruth; Satta Valentina; et al. Source: JOURNAL OF NEUROSCIENCE RESEARCH Volume: 89 Issue: 9 Pages: 1509-1518 DOI: 10.1002/jnr.22682 Published: SEP 2011
  4. Neural correlates of verbal learning in adolescent alcohol and marijuana users Author(s): Schweinsburg AD, Schweinsburg BC, Nagel BJ, et al. Source: ADDICTION Volume: 106 Issue: 3 Pages: 564-573 Published: MAR 2011
  5. Regulatory Role of Cannabinoid Receptor 1 in Stress-Induced Excitotoxicity and Neuroinflammation Author(s): Zoppi S, Nievas BGP, Madrigal JLM, et al. Source: NEUROPSYCHOPHARMACOLOGY Volume: 36 Issue: 4 Pages: 805-818 Published: MAR 2011
  6. Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials Author(s): Carter GT, Abood ME, Aggarwal SK, et al. Source: AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE Volume: 27 Issue: 5 Pages: 347-356 Published: AUG 2010
  7. Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors Author(s): Alves FHF, Crestani CC, Gomes FV, et al. Source: PHARMACOLOGICAL RESEARCH Volume: 62 Issue: 3 Pages: 228-236
  8. Influence of Feed Supplementation with Cannabis Sativa on Quality of Broilers Carcass Author(s): Khan RU, Durrani FR, Chand N, et al. Source: PAKISTAN VETERINARY JOURNAL Volume: 30 Issue: 1 Pages: 34-38
  9. White matter integrity in adolescents with histories of marijuana use and binge drinking Author(s): Jacobus J, McQueeny T, Bava S, et al. Source: NEUROTOXICOLOGY AND TERATOLOGY Volume: 31 Issue: 6 Pages: 349-355 Published: NOV-DEC 2009
  10. Cannabis use in pregnancy and early life and its consequences: animal models Author(s): Schneider M Source: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE Volume: 259 Issue: 7 Pages: 383-393 Published: OCT 2009
  11. Therapeutic Time Window of Cannabidiol Treatment on Delayed Ischemic Damage via High-Mobility Group Box1-Inhibiting Mechanism Author(s): Hayakawa K, Irie K, Sano K, et al. Source: BIOLOGICAL & PHARMACEUTICAL BULLETIN Volume: 32 Issue: 9 Pages: 1538-1544 Published: SEP 2009
  12. The role of cannabis in cognitive functioning of patients with schizophrenia Author(s): Schnell T, Koethe D, Daumann J, et al. Source: PSYCHOPHARMACOLOGY Volume: 205 Issue: 1 Pages: 45-52 Published: JUL 2009
  13. Cannabidiol: A Promising Drug for Neurodegenerative Disorders ? Author(s): Iuvone T, Esposito G, De Filippis D, et al. Source: CNS NEUROSCIENCE & THERAPEUTICS Volume: 15 Issue: 1 Pages: 65-75 Published: 2009
  14. Diabetic Retinopathy: Current Management and Experimental Therapeutic Targets Author(s): Ali TK, El-Remessy AB Source: PHARMACOTHERAPY Volume: 29 Issue: 2 Pages: 182-192 Published: FEB 2009
  15. 2-Arachidonoylglycerol Elicits Neuroprotective Effects on Excitotoxically Lesioned Dentate Gyrus Granule Cells via Abnormal-Cannabidiol-Sensitive Receptors on Microglial Cells Author(s): Kreutz S, Koch M, Bottger C, et al. Source: GLIA Volume: 57 Issue: 3 Pages: 286-294 Published: FEB 2009
  16. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism Author(s): Hayakawa K, Mishima K, Irie K, et al. Source: NEUROPHARMACOLOGY Volume: 55 Issue: 8 Pages: 1280-1286 Published: DEC 2008
  17. Study of the structure-activity relationship for theoretical molecular descriptors using density functional theory and chemometric methods in cannabinoid metabolites Author(s): Silva TBE, Pereira MA, Malta VS, et al. Source: INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY Volume: 108 Issue: 13 Special Issue: Sp. Iss. SI Pages: 2530-2539 Published: NOV 5 2008
  18. Structure determination and absolute configuration of cannabichromanone derivatives from high potency Cannabis sativa Author(s): Ahmed SA, Ross SA, Slade D, et al. Source: TETRAHEDRON LETTERS Volume: 49 Issue: 42 Pages: 6050-6053 Published: OCT 13 2008
  19. Title: Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users
    Author(s): Schilt T, de Win MML, Jager G, et al.Source: PSYCHOLOGICAL MEDICINE   Volume: 38   Issue: 9   Pages: 1309-1317   Published: SEP 2008
  20. Title: Charcot-Marie-Tooth disease  Author(s): Carter GT, Weiss MD, Han JJ, et al.
    Source: CURRENT TREATMENT OPTIONS IN NEUROLOGY   Volume: 10   Issue: 2   Pages: 94-102   Published: MAR 2008
  21. Title: JunD is involved in the antiproliferative effect of Delta(9)-tetrahydrocannabinol on human breast cancer cells Author(s): Caffarel MM, Moreno-Bueno G, Cerutti C, et al. Source: ONCOGENE Volume: 27 Issue: 37 Pages: 5033-5044 Published: AUG 28 2008
  22. Wu HY, Chu RM, Wang CC, et al. Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8 TOXICOLOGY AND APPLIED PHARMACOLOGY Volume: 226 Issue: 3 Pages: 260-270
  23. Pacher P, Hasko G Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning BRITISH JOURNAL OF PHARMACOLOGY Volume: 153 Issue: 2 Pages: 252-262
  24. Zani A, Braida D, Capurro V, et al. Delta(9)-Tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors BRITISH JOURNAL OF PHARMACOLOGY 152 (8): 1301-1311 DEC 2007
  25. Dowling GJ, Weiss SRB, Condon TP Drugs of abuse and the aging brain NEUROPSYCHOPHARMACOLOGY 33 (2): 209-218 JAN 2008
  26. Gonzalez R Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance NEUROPSYCHOLOGY REVIEW 17 (3): 347-361 SEP 2007
  27. Hayakawa K, Mishima K, Nozako M, et al. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism JOURNAL OF NEUROCHEMISTRY 102 (5): 1488-1496 SEP 2007 Times Cited: 0
  28. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, et al. Cannabis and ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users JOURNAL OF NEURAL TRANSMISSION 114 (8): 959-968 AUG 2007 Times Cited: 0 J
  29. ager G, de Win MM, Vervaeke HK, et al. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study PSYCHOPHARMACOLOGY 193 (3): 403-414 AUG 2007 Times Cited: 0
  30. Dagon Y, Avraham Y, Link G, et al. The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells NEUROBIOLOGY OF DISEASE 27 (2): 174-181 AUG 2007 Times Cited: 0
  31. Sagredo O, Ramos JA, Decio A, et al. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A(2A) receptors EUROPEAN JOURNAL OF NEUROSCIENCE 26 (4): 843-851 AUG 2007 Times Cited: 0
  32. Esposito G, Scuderi C, Savani C, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1 beta and iNOS expression BRITISH JOURNAL OF PHARMACOLOGY 151 (8): 1272-1279 AUG 2007
  33. Hayakawa K, Mishima K, Nozako M, et al. Repeated treatment with cannabidiol but not Delta(9)-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance NEUROPHARMACOLOGY 52 (4): 1079-1087 MAR 2007
  34. Garcia-Arencibia M, Gonzalez S, de Lago E, et al. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties BRAIN RESEARCH 1134 (1): 162-170 FEB 23 2007
  35. da Silva AA, Bester MJ, Pretorius E Effects of Mandrax and Cannabis on the cellular function of chick embryonic neurons ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 23 (1): 82-88 JAN 2007
  36. Pacher P, Batkai S, Kunos G The endocannabinoid system as an emerging target of pharmacotherapy PHARMACOLOGICAL REVIEWS 58 (3): 389-462 SEP 2006
  37. Bonfils PK, Reith J, Hasseldam H, et al. Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia NEUROCHEMISTRY INTERNATIONAL 49 (5): 508-518 OCT 2006
  38. Varvel SA, Wiley JL, Yang R, et al. Interactions between THC and cannabidiol in mouse models of cannabinoid activity PSYCHOPHARMACOLOGY 186 (2): 226-234 JUN 2006
  39. Zhu HJ, Wang JS, Markowitz JS, et al. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 317 (2): 850-857 MAY 2006
  40. Parrott AC MDMA in humans: factors which affect the neuropsychobiotogicat profiles of recreational ecstasy users, the integrative role of bioenergetic stress JOURNAL OF PSYCHOPHARMACOLOGY 20 (2): 147-163 MAR 2006
  41. Russo E, Guy GW A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol MED HYPOTHESES 66 (2): 234-246 2006
  42. Long LE, Malone DT, Taylor DA The pharmacological actions of cannabidiol DRUG FUTURE 30 (7): 747-753 JUL 2005
  43. Teare L, Zajicek J The use of cannabinoids in multiple sclerosis EXPERT OPIN INV DRUG 14 (7): 859-869 JUL 2005
  44. Zhuang SY, Bridges D, Grigorenko E, et al. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores NEUROPHARMACOLOGY 48 (8): 1086-1096 JUN 2005
  45. Milani RM, Parrott AC, Schifano F, et al. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms HUM PSYCHOPHARM CLIN 20 (4): 249-261 JUN 2005
  46. Kovacic P Unifying mechanism for addiction and toxicity of abused drugs with application to dopamine and glutamate mediators: Electron transfer and reactive oxygen species MED HYPOTHESES 65 (1): 90-96 2005
  47. Pryce G, Baker D Emerging properties of cannabinoid medicines in management of multiple sclerosis TRENDS NEUROSCI 28 (5): 272-276 MAY 2005
  48. Mishima K, Hayakawa K, Abe K, et al. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine(1A) receptor-dependent mechanism STROKE 36 (5): 1071-1076 MAY 2005
  49. Lastres-Becker I, Molina-Holgado F, Ramos JA, et al. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease NEUROBIOL DIS 19 (1-2): 96-107 JUN-JUL 2005
  50. Callaway JC Hempseed as a nutritional resource: An overview EUPHYTICA 140 (1-2): 65-72 2004
  51. Pertwee RG Pharmacological and therapeutic targets for Delta(9)-tetrahydrocannabinol and cannabidiol EUPHYTICA 140 (1-2): 73-82 2004
  52. Hayakawa K, Mishima K, Abe K, et al. Cannabidiol prevents infarction via the non-CBI cannabinoid receptor mechanism NEUROREPORT 15 (15): 2381-2385 OCT 25 2004
  53. Gonzalez R, Rippeth JD, Carey CL, et al. Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure DRUG ALCOHOL DEPEN 76 (2): 181-190 NOV 11 2004
  54. Juttler E, Potrovita I, Tarabin V, et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B) NEUROPHARMACOLOGY 47 (4): 580-592 SEP 2004
  55. Carter GT, Weydt P, Kyashna-Tocha M, et al. Medicinal cannabis: Rational guidelines for dosing IDRUGS 7 (5): 464-470 MAY 2004
  56. Biegon A Cannabinoids as neuroprotective agents in traumatic brain injury CURR PHARM DESIGN 10 (18): 2177-2183 2004
  57. McQueen DS, Bond SM, Smith PJW, et al. Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandarnide in anaesthetised rats EUR J PHARMACOL 491 (2-3): 181-189 MAY 3 2004
  58. Tomida I, Pertwee RG, Azuara-Blanco A Cannabinoids and glaucoma BRIT J OPHTHALMOL 88 (5): 708-712 MAY 1 2004
  59. Geller T, Loftis L, Brink DS Cerebellar infarction in adolescent males associated with acute marijuana use PEDIATRICS 113 (4): E365-E370 APR 1 2004
  60. Iuvone T, Esposito G, Esposito R, et al. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells J NEUROCHEM 89 (1): 134-141 APR 2004
  61. Jacintho JD, Kovacic P Neurotransmission and neurotoxicity by nitric oxide, catecholamines, and glutamate: Unifying themes of reactive oxygen species and electron transfer CURR MED CHEM 10 (24): 2693-2703 DEC 2003
  62. Massi P, Vaccani A, Ceruti S, et al. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines J PHARMACOL EXP THER 308 (3): 838-845 MAR 1 2004
  63. Mauler F, Horvath E, De Vry J, et al. BAY 38-7271: A novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury CNS DRUG REV 9 (4): 343-358 WIN 2003
  64. Leker RR, Gai N, Mechoulam R, et al. Drug-induced hypothermia reduces ischemic damage - Effects of the cannabinoid HU-210 STROKE 34 (8): 2000-2006 AUG 2003
  65. Braida D, Pegorini S, Arcidiacono MV, et al. Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils NEUROSCI LETT 346 (1-2): 61-64 JUL 31 2003
  66. Carter GT, Krivickas LS, Weydt P, et al. Drug therapy for amyotrophic lateral sclerosis: Where are we now? IDRUGS 6 (2): 147-153 FEB 2003
  67. Baker D, Pryce G, Giovannoni G, et al. The therapeutic potential of cannabis LANCET NEUROL 2 (5): 291-298 MAY 2003
  68. Russo EB, McPartland JM Cannabis is more than simply Delta(9)-tetrahydrocannabinol PSYCHOPHARMACOLOGY 165 (4): 431-432 FEB 2003
  69. Lorenz R A casuistic rationale for the treatment of spastic and myocloni in a childhood neurodegenerative disease: Neuronal ceroid lipofuscinosis of the type Jansky-Bielschowsky NEUROENDOCRINOL LETT 23 (5-6): 387-390 OCT-DEC 2002
  70. Kimura M, Masuda T, Yamada K, et al. Novel diphenylalkyl piperazine derivatives with dual calcium antagonistic and antioxidative activities BIOORG MED CHEM LETT 12 (15): 1947-1950 AUG 5 2002
  71. Mauler F, Mittendorf J, Horvath E, et al. Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective propertiesJ PHARMACOL EXP THER 302 (1): 359-368 JUL 2002
  72. Downer E, Boland B, Fogarty M, et al.Delta(9)-tetrahydrocannabinol induces the apoptotic pathway in cultured cortical neurones via activation of the CB1 receptorNEUROREPORT 12: (18) 3973-3978 DEC 21 2001
  73. Kirkham TC, Williams CM Endogenous cannabinoids and appetite NUTR RES REV 14: (1) 65-86 JUN 2001
  74. Campbell VA Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation
    NEUROPHARMACOLOGY 40: (5) 702-709 APR 2001
  75. Contestabile A Antioxidant strategies for neurodegenerative diseases EXPERT OPIN THER PAT 11: (4) 573-585 APR 2001